Summary
Calcium antagonists have been reported to counteract the increase by ischemia of vulnerability to ventricular fibrillation. This ability might be especially of interest in the prevention of sudden death subsequent to a major, but transitory, inadequacy between myocardial oxygen requirements and available coronary blood flow produced by exercise, emotion, etc., because death is then not related to irreversible damage of myocardial fibers. This study has been undertaken to examine the protective effect of a calcium antagonist on an animal model of this type of ischemia. This model used complete, but transient occlusion of the left anterior descending coronary artery near its origin during pacing at a constant high rate (180 beats/min) in anesthetized, open-chest pigs, most often resulting in fibrillation within 1–2 minutes after a progressive fall of the electrical fibrillation threshold. Amlodipine was the preferred calcium antagonist for this study because it is only moderately negatively inotropic. The results of the preventive administration of amlodipine was assessed by the time to onset of fibrillation. Amlodipine 0.30 mg/kg prolonged this time by 50–100% (p < 0.05) without appreciable impairment of blood pressure or myocardial contractility. Concurrently, amlodipine delayed the shortening of the monophasic action potential duration, the lengthening of conduction time, and the alterations of ST segments and T waves linked to ischemic depolarization. Consequently, when given experimentally before the occurrence of major, but transitory ischemia, amlodipine protected against fibrillation. Similarly, in clinical settings it ought to delay sudden death that may occur as a result of a major but transitory inadequacy between myocardial oxygen requirements and available coronary blood flow.
Similar content being viewed by others
References
Roeland J, Klootwijk P, Lubsen J, Janse MJ. Sudden death during long-term ambulatory monitoring. Eur Heart J 1984; 5: 7–20.
Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989; 69: 1049–1169.
Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatment following myocardial infarction. JAMA 1988; 260: 2088–2093.
Hugenholtz PG, Serruys PW, Fleckenstein A, Nayler W. Why calcium antagonists are most useful before or during early myocardial ischemia. Prac Cardiol 1986; 12: 62–72.
Nayler WG, Panagiotopoulos S, Elz JS, Sturrock WJ. Fundamental mechanisms of action of calcium antagonists in myocardial ischemia. Am J Cardiol 1987; 59: 75B-83B.
Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol 1987; 59: 84B-94B.
Brooks WW, Verrier RL, Lown B. Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Cardiovasc Res 1980; 14: 295–302.
Clusin WT, Bristow MR, Karagueuzian HS, Katzung BG, Schroeder JS. Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? Am J Cardiol 1982; 49: 606–626.
Surawicz B. Role of calcium-blocking agents in treatment of cardiac arrhythmias related to myocardial ischemia. Am Heart J 1982; 103: 698–706.
Clusin WT, Buchbinder M, Ellis AK, Kernoff RS, Giacomini JC, Harrison DC. Reduction of ischemic depolarization by the calcium channel blocker diltiazem. Circ Res 1984; 54: 10–20.
Timour Q, Larbre JP, Aupetit JF, et al. Protection against ischemic ventricular fibrillation by blocking agents of myocardial cell calciu influx. Electrophysiological study in the pig in situ heart. Fundam Clin Pharmacol 1991; 5: 641–644.
Aupetit JF, Timour Q, Freysz M, et al. Vulnerability to ventricular fibrillation related to ischemia. Comparison of the acute effects of β-blockers and calcium antagonists. Arch Int Pharmacodyn 1994; 327: 25–39.
Dodd MG, Gardiner DG, Carter AJ, Sutton MR, Burges RA. The haemodynamic properties of amlodipine in anaesthetized and conscious dogs. Comparison with nitrendipine and influence of β-adrenergic blockade. Cardiovasc Drugs Ther 1989; 3: 545–555.
The Danish Verapamil Infarction Trial II (DAVIT II). Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990; 66: 779–785.
Hansen JF. Treatment with verapamil after acute myocardial infarction. Drugs 1991; 42 (Suppl 2): 43–53.
James RGG, Arnold JMO, Allen JD, Pantridge JF, Shanks RG. The effects of heart rate, myocardial ischemia and vagal stimulation on the threshold for ventricular fibrillation. Circulation 1977; 55: 311–317.
Hagar JM, Hale SL, Kloner RA. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary occlusion and reperfusion in the rat. Circ Res 1991; 68: 61–68.
Vegh A, Komori S, Szekeres L, Parratt JR. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 1992; 26: 487–495.
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia. A delay in lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–1136.
Aupetit JF, Timour Q, Chevrel G, Loufoua-Moundanga J, Omar S, Faucon G. Attenuation of the ischemia-induced fall of electrical threshold for fibrillation by a calcium antagonist, dilitiazem. Naunyn Schmiedeberg's Arch Pharmacol 1993; 348: 509–514.
Williams DM, Cubeddu L. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988; 28: 990–994.
Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S55-S59.
Kaumann AJ, Aramendia P. Prevention of ventricular fibrillation induced by coronary ligation. J Pharmacol Exp Ther 1968; 164: 326–332.
Danish Study Group on Verapamil in Myocardial Infarction (Danish Verapamil Infarction Trial, DAVIT I). Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516–528.
Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–392.
Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina. An overview. Br Med J 1989; 299: 1187–1192.
Rafflenbeul W, Ebner F. Myocardial infarction. Secondary prevention with nifedipine. Drugs 1991; 42 (Suppl 2): 38–42.
Blake K, Clusin WT. Effect of diltiazem on ischemic myocardial depolarization and extracellular K+ accumulation. Eur J Pharmacol 1986; 127: 261–265.
Heijnis JB, Coronel R, VanZwieten PA. The effects of calcium antagonists on extracellular potassium accumulation during global ischemia in isolated perfused rat hearts. Cardiovasc Drugs Ther 1991; 5: 1035–1041.
Gettes LS, Cascio WE, Johnson T, Fleet WF. Local myocardial biochemical and ionic alterations during myocardial ischemia and reperfusion. Drugs 1991; 42 (Suppl 1): 7–13.
Lyons CJ, Burgess MJ, Abildskov JA. Effects of acute hyperkalemia on cardiac excitability. Am Heart J 1977; 94: 755–763.
Weidmann S. The effect of the cardiac membrane potential on the rapid availability of sodium carrying system. J Physiol (Lond) 1955; 127: 213–214.
Fondacaro JD, Han J, Yoon MS. Effects of verapamil on ventricular rhythm during acute coronary occlusion. Am Heart J 1978; 96: 81–86.
Kimura S, Bassett AL, Kohya T, Kozlovski PL, Myerburg RJ. Regional effect of verapamil on recovery of excitability and conduction time in experimental ischemia. Circulation 1987; 76: 1146–1154.
Elharrar V, Gaum WE, Zipes DP. Effects of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol 1977; 39: 544–549.
Peter T, Fujimoto T, Hamamoto H, Mandel WJ. Comparative study of the effect of slow channel inhibiting agents on ischemia-induced conduction delay as relevant to the genesis of ventricular fibrillation. Am Heart J 1983; 106: 1023–1028.
Lange RL, Ingwall J, Hale SL, Alker KJ, Braunwald E, Kloner RA. Preservation of high energy phosphates by verapamil in reperfused myocardium. Circulation 1984; 70: 734–741.
Thandroyen FT. Protective action of calcium channel antagonist agents against ventricular fibrillation in the isolated perfused rat heart. J Mol Cell Cardiol 1982; 14: 21–32.
Coraboeuf E. Ionic basis of electrical activity in cardiac tissues. Am J Physiol 1978; 234: H101-H116.
Reuter H. Ion channels in cardiac cell membrane. Annu Rev Physiol 1984; 46: 473–484.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Timour, Q., Bui-Xuan, B., Faucon, G. et al. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drug Ther 10, 447–454 (1996). https://doi.org/10.1007/BF00051109
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00051109